Additionally, the strong immunohistochemistry signal of PSPH in high grade gliomas presented as an example that the dysregulated SMGMs could be used as pathological biomarkers to identify the most aggressive gliomas (Supplementary Figure S3). This evidence concerns the gene PSPH and central nervous system cancer.